Orasis Pharmaceuticals
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Marketside Ave Ste 404-324, Ponte Ve...Website
www.orasis-pharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Orasis Pharmaceuticals
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI, for presbyopia as an alternative to reading glasses.Explore more
Orasis Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orasis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Orasis Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Orasis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Orasis Pharmaceuticals has new funding data
Product Launch: Get notified when Orasis Pharmaceuticals launches new products
Click to see if Orasis Pharmaceuticals had a recent Job posting/layoffs
Check out if Orasis Pharmaceuticals is spiking on competitors!
Check if Orasis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Orasis Pharmaceuticals
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Orasis Pharmaceuticals as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Orasis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orasis Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orasis Pharmaceuticals.
Orasis Pharmaceuticals financials insights
Gather financial insights about Orasis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$13M
2020
Series C
$30M
2024
Debt
$15M
Series D
$68M
Orasis Pharmaceuticals Tech Stack
A closer look at the technologies used by Orasis Pharmaceuticals
Most Recent Scoops
Project
Product Marketing, Product Management, Business Development, Marketing Operations, Operations
Hiring Plans
Orasis Pharmaceuticals has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Orasis Pharmaceuticals has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Funding
Funding
Funding
Funding
Orasis Pharmaceuticals News & Media
ORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIA
Submission of New Drug Application (NDA) in Australia by Aspen Pharmacare Australia (Aspen Australia) marks the first ex-U.S. regulatory submission (known as QLOSI® in the U.S.) PONTE VEDRA, Fla., July 15, 2026 /PRNewswire/ -- Orasis Pharmaceuticals and Aspen Australia announced that...ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUT
Since its U.S. launch in April 2025, Qlosi has seen strong market adoption and refill rates Eye care professionals (ECPs) can request Starter Packs directly through their Account Manager or by visiting Orasis.MySampleCloset.com PONTE VEDRA, Fla., Nov. 13, 2025 /PRNewswire/ -- Orasis...Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea
Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales in the Korean Market Additional Capital Follows Orasis' Recent $78 Million Financing to Support Commercial Launch of Qlosi in the United States PONTE VEDRA, Fla., Oct....Orasis Pharmaceuticals Strengthens Leadership Team with Key Hires to Support the Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%
PONTE VEDRA, Fla., Oct. 14, 2024 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced the appointments of Jeff Francis as Vice President of Sales and Sam Fakhoury as Vice President of Quality and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Orasis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI, for presbyopia as an alternative to reading glasses.... Read More
